Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation

Transplantation

Volumn 79, Issue 10, 2005, Pages 1411-1416

  Mattsson, Jonas ^a   Remberger, Mats ^a   Andersson, Olof ^a   Sundberg, Berit ^a   Nord, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bronchiolitis obliterans; Chronic graft versus host disease; Clara cell secretory protein (CC16); Small airway disease; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; PROTEIN CC16; SECRETORY PROTEIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT VERSUS HOST DISEASE; CLARA CELL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; SAMPLING; SENSITIVITY AND SPECIFICITY; SMALL AIRWAY DISEASE; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; BRONCHIOLITIS OBLITERANS; CASE-CONTROL STUDIES; CHILD; EARLY DIAGNOSIS; GRAFT VS HOST DISEASE; HUMANS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; UTEROGLOBIN;

EID: 19544386118     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000158354.39635.AB     Document Type: Article

References (22)

1. Breuer R, Lossos IS, Berkman N, et al. Pulmonary complications of bone marrow transplantation. Respir Med 1993; 87(8): 571.
2. Ringden O, Deeg J. Clinical spectrum of graft-verus-host disease. In: Ferrara J, Deeg J, Burakoff S, eds. Graft-vs.-Host Disease. New York, Marcel Dekker, Inc. 1996, p 525.
3. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995; 26(6): 668.
4. King TE Jr. Overview of bronchiolitis. Clin Chest Med 1993; 14(4): 607.
5. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28(5): 425.
6. Clark JG, Crawford SW, Madtes DK, et al. Obstructive lung disease after allogeneic marrow transplantation: Clinical presentation and course. Ann Intern Med 1989; 111(5): 368.
7. Hermans C, Bernard A. Lung epithelium-specific proteins: Characteristics and potential applications as markers. Am J Respir Crit Care Med 1999; 159(2): 646.
8. Stripp BR, Reynolds SD, Plopper CG, et al. Pulmonary phenotype of CCSP/UG deficient mice: A consequence of CCSP deficiency or altered Clara cell function? Ann N Y Acad Sci 2000; 923: 202.
9. Nord M, Schubert K, Cassel TN, et al. Decreased serum and bronchoalveolar lavage levels of Clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients. Transplantation 2002; 73(8): 1264.
10. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91(3): 756.
11. Mattsson J, Uzunel M, Brune M, et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2001; 115(4): 935.
12. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343(11): 750.
13. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314(12): 729.
14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18(4): 295.
15. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: A retrospective analysis. Bone Marrow Transplant 1994; 14(4): 601.
16. Ringden O, Remberger M, Carlens S, et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 1998; 66(5): 620.
17. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168(2): 208.
18. Dudek AZ, Mahaseth H, DeFor TE, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: Analysis of risk factors and treatment outcomes. Dial Blood Marrow Transplant 2003; 9(10): 657.
19. Lesur O, Bernard A, Arsalane K, et al. Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med 1995; 152(1): 290.
20. Dierynck I, Bernard A, Roels H, et al. Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16. Am J Respir Cell Mol Biol 1995; 12(2): 205.
21. Hayry P. Molecular pathology of acute and chronic rejection. Transplant Proc 1994; 26(6): 3280.
22. Riise GC, Williams A, Kjellstrom C, et al. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 1998; 12(1): 82.